ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 18 Jan 2021
Last Updated on 13 Sep 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended to:
  • Reclassify infliximab biosimilar (Remsima) 100 mg vial from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
  • List infliximab biosimilar (Ixifi) 100 mg vial on the SDL
in view of favourable cost effectiveness compared to other anti-tumour necrosis factor alfa (anti-TNFα) biologics at the prices proposed by the manufacturers.

Subsidy status
SDL subsidy will apply for all registered indications of infliximab biosimilar 100 mg vial (Remsima and Ixifi) in Singapore:
  • Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis or Crohn’s disease;
  • Children aged 6 years or older with severe active Crohn’s disease; and
  • Children aged 6 years or older with moderately to severely active ulcerative colitis.
SDL subsidy does not apply to proprietary infliximab 100 mg vial (Remicade) or other brands of infliximab biosimilars.

Previous versions of the guidance may be found here
Intravenous infliximab biosimilar for treating inflammatory conditions (Updated 13 Sep 2024) Biosimilar Clinician Fact Sheet (1 Mar 2018)